a developer of pharmaceuticals for pulmonary disease
Industry Biotechnology
A.I.dvisor tells us that PULM and INM have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PULM and INM's prices will move in lockstep.
Ticker / NAME | Correlation To PULM | 1D Price Change % | ||
---|---|---|---|---|
PULM | 100% | +32.02% | ||
INM - PULM | 29% Poorly correlated | +2085.89% | ||
CRIS - PULM | 24% Poorly correlated | +1.27% | ||
CERO - PULM | 23% Poorly correlated | -11.66% | ||
MOLN - PULM | 23% Poorly correlated | -4.72% | ||
IFRX - PULM | 22% Poorly correlated | +18.71% | ||
More |
Ticker / NAME | Correlation To PULM | 1D Price Change % |
---|---|---|
PULM | 100% | +32.02% |
biotechnology theme (238 stocks) | -0% Poorly correlated | -1.76% |
drugs theme (254 stocks) | -3% Poorly correlated | -1.67% |
diseases theme (41 stocks) | -4% Poorly correlated | -1.10% |
pharmaceuticals theme (159 stocks) | -11% Poorly correlated | -1.90% |